GlobeNewsWire
28 Jul 2026, 11:47 UTC · 4h ago
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
28 Jul 2026, 11:47 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Clearmind Medicine successfully completed treatment for all 24 participants in Part A of its FDA-regulated Phase I/II trial for CMND-100 in Alcohol Use Disorder. — Successful completion of a clinical phase is a positive milestone that reduces operational risk and brings the drug closer to potential commercialization.
+0.40The company is currently assessing the dataset and intends to initiate the next stage of the clinical program if results remain favorable. — This indicates a clear path forward for the asset, though the actual market move depends on the upcoming data readout.
+0.20Which stocks this story touches
The company successfully completed Part A of its FDA-regulated Phase I/II clinical trial for its lead candidate CMND-100.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
48m ago
